Cargando…

Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways

BACKGROUND: Despite recent advances in diagnosis and treatment, prostate cancer (PCa) remains the leading cause of cancer-related deaths in men. Current treatments offered in the clinics are often toxic and have severe side effects. Hence, to treat and manage PCa, new agents with fewer side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Ashley B., Mir, Hina, Kapur, Neeraj, Gales, Dominique N., Carriere, Patrick P., Singh, Shailesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001031/
https://www.ncbi.nlm.nih.gov/pubmed/29898731
http://dx.doi.org/10.1186/s12957-018-1400-z
_version_ 1783331895565615104
author Ward, Ashley B.
Mir, Hina
Kapur, Neeraj
Gales, Dominique N.
Carriere, Patrick P.
Singh, Shailesh
author_facet Ward, Ashley B.
Mir, Hina
Kapur, Neeraj
Gales, Dominique N.
Carriere, Patrick P.
Singh, Shailesh
author_sort Ward, Ashley B.
collection PubMed
description BACKGROUND: Despite recent advances in diagnosis and treatment, prostate cancer (PCa) remains the leading cause of cancer-related deaths in men. Current treatments offered in the clinics are often toxic and have severe side effects. Hence, to treat and manage PCa, new agents with fewer side effects or having potential to reduce side effects of conventional therapy are needed. In this study, we show anti-cancer effects of quercetin, an abundant bioflavonoid commonly used to treat prostatitis, and defined quercetin-induced cellular and molecular changes leading to PCa cell death. METHODS: Cell viability was assessed using MTT. Cell death mode, mitochondrial outer membrane potential, and oxidative stress levels were determined by flow cytometry using Annexin V-7 AAD dual staining kit, JC-1 dye, and ROS detection kit, respectively. Antibody microarray and western blot were used to delineate the molecular changes induced by quercetin. RESULTS: PCa cells treated with various concentrations of quercetin showed time- and dose-dependent decrease in cell viability compared to controls, without affecting normal prostate epithelial cells. Quercetin led to apoptotic and necrotic cell death in PCa cells by affecting the mitochondrial integrity and disturbing the ROS homeostasis depending upon the genetic makeup and oxidative status of the cells. LNCaP and PC-3 cells that have an oxidative cellular environment showed ROS quenching after quercetin treatment while DU-145 showed rise in ROS levels despite having a highly reductive environment. Opposing effects of quercetin were also observed on the pro-survival pathways of PCa cells. PCa cells with mutated p53 (DU-145) and increased ROS showed significant reduction in the activation of pro-survival Akt pathway while Raf/MEK were activated in response to quercetin. PC-3 cells lacking p53 and PTEN with reduced ROS levels showed significant activation of Akt and NF-κB pathway. Although some of these changes are commonly associated with oncogenic response, the cumulative effect of these alterations is PCa cell death. CONCLUSIONS: Our results demonstrated quercetin exerts its anti-cancer effects by modulating ROS, Akt, and NF-κB pathways. Quercetin could be used as a chemopreventive option as well as in combination with chemotherapeutic drugs to improve clinical outcomes of PCa patients.
format Online
Article
Text
id pubmed-6001031
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60010312018-06-26 Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways Ward, Ashley B. Mir, Hina Kapur, Neeraj Gales, Dominique N. Carriere, Patrick P. Singh, Shailesh World J Surg Oncol Research BACKGROUND: Despite recent advances in diagnosis and treatment, prostate cancer (PCa) remains the leading cause of cancer-related deaths in men. Current treatments offered in the clinics are often toxic and have severe side effects. Hence, to treat and manage PCa, new agents with fewer side effects or having potential to reduce side effects of conventional therapy are needed. In this study, we show anti-cancer effects of quercetin, an abundant bioflavonoid commonly used to treat prostatitis, and defined quercetin-induced cellular and molecular changes leading to PCa cell death. METHODS: Cell viability was assessed using MTT. Cell death mode, mitochondrial outer membrane potential, and oxidative stress levels were determined by flow cytometry using Annexin V-7 AAD dual staining kit, JC-1 dye, and ROS detection kit, respectively. Antibody microarray and western blot were used to delineate the molecular changes induced by quercetin. RESULTS: PCa cells treated with various concentrations of quercetin showed time- and dose-dependent decrease in cell viability compared to controls, without affecting normal prostate epithelial cells. Quercetin led to apoptotic and necrotic cell death in PCa cells by affecting the mitochondrial integrity and disturbing the ROS homeostasis depending upon the genetic makeup and oxidative status of the cells. LNCaP and PC-3 cells that have an oxidative cellular environment showed ROS quenching after quercetin treatment while DU-145 showed rise in ROS levels despite having a highly reductive environment. Opposing effects of quercetin were also observed on the pro-survival pathways of PCa cells. PCa cells with mutated p53 (DU-145) and increased ROS showed significant reduction in the activation of pro-survival Akt pathway while Raf/MEK were activated in response to quercetin. PC-3 cells lacking p53 and PTEN with reduced ROS levels showed significant activation of Akt and NF-κB pathway. Although some of these changes are commonly associated with oncogenic response, the cumulative effect of these alterations is PCa cell death. CONCLUSIONS: Our results demonstrated quercetin exerts its anti-cancer effects by modulating ROS, Akt, and NF-κB pathways. Quercetin could be used as a chemopreventive option as well as in combination with chemotherapeutic drugs to improve clinical outcomes of PCa patients. BioMed Central 2018-06-14 /pmc/articles/PMC6001031/ /pubmed/29898731 http://dx.doi.org/10.1186/s12957-018-1400-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ward, Ashley B.
Mir, Hina
Kapur, Neeraj
Gales, Dominique N.
Carriere, Patrick P.
Singh, Shailesh
Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title_full Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title_fullStr Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title_full_unstemmed Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title_short Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
title_sort quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001031/
https://www.ncbi.nlm.nih.gov/pubmed/29898731
http://dx.doi.org/10.1186/s12957-018-1400-z
work_keys_str_mv AT wardashleyb quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways
AT mirhina quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways
AT kapurneeraj quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways
AT galesdominiquen quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways
AT carrierepatrickp quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways
AT singhshailesh quercetininhibitsprostatecancerbyattenuatingcellsurvivalandinhibitingantiapoptoticpathways